Metabolic Transformation of Gentiopicrin, a Liver Protective Active Ingredient, Based on Intestinal Bacteria

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Nov 25

PMID 38005297

Authors

Jie Fu

Hang Yu

Qinglan Guo

Yanan Wang

Hui Xu

Jinyue Lu

Jiachun Hu

Yan Wang

Affiliations

Soon will be listed here.

Abstract

Gentiopicrin, the main component of the famous Chinese patent medicine Long Dan Xie Gan Wan, has the characteristics of fast absorption in vivo and low bioavailability. Intestinal bacteria play an important role in the absorption and pharmacokinetics of oral drugs. In this study, the metabolic transformation of gentiopicrin by intestinal bacteria was examined. High-performance liquid chromatography coupled with ion trap time-of-flight mass spectrometry (LC/MS-IT-TOF) and nuclear magnetic resonance (NMR) were used, and six metabolites were identified, including reduction products (G-M1, G-M2, G-M4, and G-M6), a hydrolytic product (G-M3), and a dehydration product (G-M5) of gentiopicrin aglycone after hydrolysis, reduction, and dehydration reactions were performed by the intestinal flora. This is the first time that chiral metabolites of gentiopicrin (G-M1 and G-M2) were found in this study. In addition, the precursors of glucuronic acid conjugates previously reported in vivo may have come from the intestinal bacterial metabolites G-M1, G-M2, and G-M3. In addition, the metabolic transformation of gentiopicrin in liver microsomes was studied in vitro, and it was found that gentiopicrin did not undergo metabolic transformation under the action of liver microsomes. It is suggested that gentiopicroside may be metabolized in the intestine. This study provides both new insight regarding the investigation of effective substances and an exploration of the pharmacodynamic and toxicological properties of gentiopicrin.

References

Yang H, Shang Y, Jin Q, Wu Y, Liu J, Qiao C . Gentiopicroside Ameliorates the Progression from Hepatic Steatosis to Fibrosis Induced by Chronic Alcohol Intake. Biomol Ther (Seoul). 2020; 28(4):320-327. PMC: 7327139. DOI: 10.4062/biomolther.2020.008. View

Qin J, Li R, Raes J, Arumugam M, Burgdorf K, Manichanh C . A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464(7285):59-65. PMC: 3779803. DOI: 10.1038/nature08821. View

Laparra J, Sanz Y . Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res. 2009; 61(3):219-25. DOI: 10.1016/j.phrs.2009.11.001. View

Xu L, Liu C, Han Z, Han H, Yang L, Wang Z . Microbial Biotransformation of Iridoid Glycosides from Gentiana Rigescens by Penicillium Brasilianum. Chem Biodivers. 2020; 17(12):e2000676. DOI: 10.1002/cbdv.202000676. View

Hassan N, Ahamad J, Amin S, Mujeeb M, Mir S . Rapid preparative isolation of erythrocentaurin from Enicostemma littorale by medium-pressure liquid chromatography, its estimation by high-pressure thin-layer chromatography, and its α-amylase inhibitory activity. J Sep Sci. 2014; 38(4):592-8. DOI: 10.1002/jssc.201401030. View

Yang X, Song C . [Studies on the metabolism of gentiopicroside by rat intestinal flora]. Zhongguo Zhong Yao Za Zhi. 2003; 25(11):673-6. View

Gupta A, Saha S, Khanna S . Therapies to modulate gut microbiota: Past, present and future. World J Gastroenterol. 2020; 26(8):777-788. PMC: 7052537. DOI: 10.3748/wjg.v26.i8.777. View

Xiao H, Sun X, Lin Z, Yang Y, Zhang M, Xu Z . Gentiopicroside targets PAQR3 to activate the PI3K/AKT signaling pathway and ameliorate disordered glucose and lipid metabolism. Acta Pharm Sin B. 2022; 12(6):2887-2904. PMC: 9214054. DOI: 10.1016/j.apsb.2021.12.023. View

Zhao Z, Fu J, Ma S, Peng R, Yu J, Cong L . Gut-brain axis metabolic pathway regulates antidepressant efficacy of albiflorin. Theranostics. 2019; 8(21):5945-5959. PMC: 6299426. DOI: 10.7150/thno.28068. View

10.

Wu S, Ning Y, Zhao Y, Sun W, Thorimbert S, Dechoux L . Research Progress of Natural Product Gentiopicroside - a Secoiridoid Compound. Mini Rev Med Chem. 2016; 17(1):62-77. DOI: 10.2174/1389557516666160624124127. View

11.

Wilson I, Nicholson J . Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 2016; 179:204-222. PMC: 5718288. DOI: 10.1016/j.trsl.2016.08.002. View

12.

Zeng W, Han H, Tao Y, Yang L, Wang Z, Chen K . Identification of bio-active metabolites of gentiopicroside by UPLC/Q-TOF MS and NMR. Biomed Chromatogr. 2013; 27(9):1129-36. DOI: 10.1002/bmc.2917. View

13.

Han H, Xiong A, He C, Liu Q, Yang L, Wang Z . Combination of UHPLC/Q-TOF-MS, NMR spectroscopy, and ECD calculation for screening and identification of reactive metabolites of gentiopicroside in humans. Anal Bioanal Chem. 2014; 406(6):1781-93. DOI: 10.1007/s00216-013-7572-z. View

14.

Wang Z, Tang S, Jin Y, Zhang Y, Hattori M, Zhang H . Two main metabolites of gentiopicroside detected in rat plasma by LC-TOF-MS following 2,4-dinitrophenylhydrazine derivatization. J Pharm Biomed Anal. 2015; 107:1-6. DOI: 10.1016/j.jpba.2014.12.003. View

15.

Wang C, Wang Z, Bligh S, White K, White C . Pharmacokinetics and tissue distribution of gentiopicroside following oral and intravenous administration in mice. Eur J Drug Metab Pharmacokinet. 2004; 29(3):199-203. DOI: 10.1007/BF03190598. View

16.

Hattori M, KOBASHI K, Namba T . Metabolism of gentiopicroside (gentiopicrin) by human intestinal bacteria. Chem Pharm Bull (Tokyo). 1989; 37(9):2435-7. DOI: 10.1248/cpb.37.2435. View

17.

Xu J, Chen H, Li S . Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota. Med Res Rev. 2017; 37(5):1140-1185. DOI: 10.1002/med.21431. View

18.

Zhang Y, Yang X, Wang S, Song S, Yang X . Gentiopicroside prevents alcoholic liver damage by improving mitochondrial dysfunction in the rat model. Phytother Res. 2020; 35(4):2230-2251. DOI: 10.1002/ptr.6981. View

19.

Zhang J, Zhang J, Wang R . Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 2018; 50(3):357-368. DOI: 10.1080/03602532.2018.1497647. View

20.

Tilg H, Kaser A . Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011; 121(6):2126-32. PMC: 3104783. DOI: 10.1172/JCI58109. View